Search

Displaying results 2151 - 2160 of 8411 in total
  1. Drug

    PH-797804

    go.drugbank.com/drugs/DB07941
    Investigational

    PH-797804 has been investigated for the treatment of Osteoarthritis.

  2. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors

  3. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses. … [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand

  4. Drug

    Tocofersolan

    go.drugbank.com/drugs/DB11635
    Approved

    Tocofersolan is an oral treatment of vitamin E deficiency due to digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis. … D-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis [L2371].

    Synonyms: D-.ALPHA.-TOCOPHEROL POLYETHYLENE GLYCOL 1000 SUCCINATECategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    Lotiglipron has a monoisotopic molecular weight of 574.2 Da. … Lotiglipron is under investigation in clinical trial NCT05579977 (Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People

  6. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    With the price per pill set at $1000, a 12-week treatment can cost upwards of $84,000 per patient [A19636]. … This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure

    Categories: P-glycoprotein substrates
  7. Drug

    Cholestyramine

    go.drugbank.com/drugs/DB01432
    ApprovedInvestigational

    Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.

    Products: VASOSAN P BTL, VASOSAN P DOSE
  8. Drug

    Anumigilimab

    go.drugbank.com/drugs/DB16359
    Investigational

    CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory ...

  9. Drug

    Benzoic acid

    go.drugbank.com/drugs/DB03793
    ApprovedInvestigational

    As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids. … Recent research shows that sodium benzoate may be beneficial as an add-on therapy (1 gram/day) in schizophrenia. Total Positive and Negative Syndrome Scale scores dropped by 21% compared to placebo.

    Mixtures: Prosed/DS
  10. Drug

    Alclofenac

    go.drugbank.com/drugs/DB13167
    ApprovedWithdrawn

    Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.